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Effects of phenethyl isothiocyanate (PEITC) have been investigated in human leukemia cells (U937, Jurkat, and HL-60) as well as
in primary human acute myeloid leukemia (AML) cells in relation to apoptosis and cell signaling events. Exposure of cells to
PEITC resulted in pronounced increase in the activation of caspase-3, -8, -9, cleavage/degradation of PARP, and apoptosis in
dose- and time-dependent manners. These events were accompanied by the caspase-independent downregulation of Mcl-1,
inactivation of Akt, as well as activation of Jun N-terminal kinase (JNK). Inhibition of PI3K/Akt by LY294002 signiﬁcantly
enhanced PEITC-induced apoptosis. Conversely, enforced activation of Akt by a constitutively active Akt construct markedly
abrogatedPEITC-mediated JNKactivation,Mcl-1downregulation,caspase activation,andapoptosis,andalsointerruptionofthe
JNK pathway by pharmacological or genetically (e.g., siRNA) attenuated PEITC-induced apoptosis. Finally, administration of
PEITC markedly inhibited tumor growth and induced apoptosis in U937 xenograft model in association with inactivation of Akt,
activation of JNK, as well as downregulation of Mcl-1. Taken together, these ﬁndings represent a novel mechanism by which
agents targeting Akt/JNK/Mcl-1 pathway potentiate PEITC lethality in transformed and primary human leukemia cells and
inhibitory activity of tumor growth of U937 xenograft model.
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Epidemiological studies support the evidence that the con-
sumption of cruciferous vegetables has long been associated
with a reduced risk in the occurrence of cancer at various
sites, including the prostate, lung, breast, and colon.
1 The
anticarcinogenic effect of cruciferous vegetables is attributed
to organic isothiocyanates (ITCs), which are present in a
variety of edible cruciferous vegetables such as broccoli,
watercress, cabbage, and so on.
1 Phenethyl isothiocyanate
(PEITC) is one of the ITC family of compounds that
has attracted a great deal of attention owing to its
remarkable cancer chemopreventive activity.
2 For
example, PEITC administration has been shown to signiﬁcantly
inhibit 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-in-
duced pulmonary neoplasia in rats and mice,
3,4 N-nitroso-
benzylmethylamine-induced esophageal cancer in rats,
5 and
benzo[a]pyrene-induced carcinogenesis in mice.
6 A possible
mechanism by which PEITC protects against cancer is
through cell cycle arrest and apoptosis.
7 Therefore, an
understanding of the mechanism of PEITC-related lethality
is important for its further development as a clinically
useful chemopreventive or therapeutic agent because this
knowledge could lead to the identiﬁcation of mechanism-
based biomarkers potentially useful in future clinical trials.
Recent studies have shown that PEITC is a strong inducer
of apoptosis in various cancer cell types. Xiao et al.
8 have
shown that PEITC-induced apoptosis involved extracellular
signal-regulated kinase (ERK) activation and the cleavage of
procaspase-3, procaspase-8, and procaspase-9 in PC-3
cells. Chen et al.
9 have reported that apoptosis induction by
PEITC is in association with sustained activation of c-Jun
NH2-terminal kinase in Jurkat cells. Huang et al.
10 provided
convincing evidence to suggest an essential role for p53 in
apoptosis induction by PEITC. More recent studies have
indicated that PEITC-induced cell death involves mitochondria
-mediated activation of caspase cascade and generation of
reactive oxygen species (ROS).
11,12 Previous studies have
shown that PEITC inhibited growth and induced apoptosis of
human leukemia (HL-60) cells, and glutathione metabolism
may be involved in PEITC-related lethality.
13 However, the
molecularmechanismsofPEITC-inducedapoptosisinhuman
leukemia cells are not fully deﬁned. There is no available
information concerning PEITC’s in vivo efﬁcacy against
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www.nature.com/cddisleukemia. This study provides experimental evidence to
indicate, for the ﬁrst time, that the cell death caused by
PEITC is initiated by the inactivation of Akt, leading, in turn, to
Jun N-terminal kinase (JNK) activation, and culminating in
Mcl-1 downregulation. In addition, we show that administra-
tion of PEITC signiﬁcantly inhibits the tumor growth of U937
xenograftsinSCIDmiceinassociationwithinactivationofAkt,
activation of JNK, as well as induction of apoptosis.
Results
PEITC induces apoptosis, caspase activation, and PARP
cleavage in U937 human leukemia cells in dose- and
time-dependent manners. A dose-dependent study of
U937 cells exposed to various concentrations of PEITC for
3 and 6h was shown in Figure 1a; modest degrees of
apoptosis were noted at 4mM PEITC concentration, which
increased substantially at concentration of 6mM. These
events became very extensive at concentration of 8mM. A
time-course study of cells exposed to 8mM PEITC revealed a
signiﬁcant increase in apoptosis as early as 3h, and reached
near-maximal levels after 6h of drug exposure (Figure 1b).
Consistent with these results, exposure of cells to 4mM
PEITC for 3 and 6h revealed a moderate increase in
cleavage/activation of caspase-3, -8, and -9, as well as PARP
degradation and a marked increase at concentrations Z6mM
(Figure 1c). Time-course study of cells exposed to 8mM
PEITC revealed moderate increases in cleavage/activation of
caspase-3, -8, and -9, as well as PARP degradation 2 or 3h
after drug exposure. These events became apparent at 4h,
and reached near-maximal levels at 6h after drug exposure
(Figure 1d).
Exposure of U937 cells to PEITC results in rapid
decrease in Mcl-1 protein level. To understand the
critical roles of Bcl-2 family proteins have in apoptosis,
expression of these proteins in U937 cells was monitored
following treatment with PEITC. As shown in Figure 2a,
exposure of cells to 4mM PEITC for 3 and 6h resulted in
moderate decrease in the expression of Mcl-1. These events
became apparent at 6mM and very extensive at 8mM after
drug exposure. A time-course study showed that exposure of
U937 cells to 8mM PEITC resulted in modest decrease in the
expression of Mcl-1 as early as 2h after drug exposure.
These events became apparent at 3h and very extensive
at 4h after drug exposure (Figure 2b). In contrast, the
expression of other Bcl-2 family proteins such as XIAP, Bcl-2,
Bcl-xL, Bax, and Bad remained unaffected (Figures 2a and
b). Taken together, these ﬁndings show that downregulation
of Mcl-1 may be responsible for PEITC lethality in U937 cells.
Exposure of U937 cells to PEITC results in marked
decrease in levels of phospho-Akt and signiﬁcant
increase in the expression of phospho-JNK. Effects
of PEITC on various signal-transduction pathways
implicated in apoptosis regulation were also investigated.
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Figure 1 Phenethyl isothiocyanate (PEITC) signiﬁcantly induces apoptosis,
caspase activation, and poly(ADP-ribose) polymerase (PARP) cleavage in U937
human leukemia cells in dose- and time-dependent manners. (a) U937 cells were
treated without or with various concentrations of PEITC as indicated for 3 and 6h.
(b) U937cell were treated without or with 8mM PEITC for 1, 3, 6, 9, 12, and 24h.
Cells were stained with Annexin V/propidium iodide (PI), and apoptosis was
determined using ﬂow cytometry as described in Materials and Methods. (c) U937
cellswere treatedwithout or with variousconcentrations of PEITCas indicatedfor 3
and6h.(d)U937cellsweretreatedwithoutorwith 8mMPEITCfor0.5,1, 2,3,4,6,
12, and 24h. After treatment of U937 cells with the indicated PEITC concentration
or the indicated time interval, total cellular extracts were prepared and subjected to
western blot assay using antibodies against PARP, cleaved-caspase-3
(C-Caspase-3), caspase-8, and cleaved-caspase-9 (C-Caspase-9). Each lane
was loaded with 30mg protein. Blots were subsequently stripped and reprobed with
antibody against b-actin to ensure equivalent loading and transfer. Two additional
studies yielded equivalent results
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Figure 2 Phenethyl isothiocyanate (PEITC) induces downregulation of Mcl-1,
inactivation of Akt, and activation of Jun N-terminal kinase (JNK) in U937 cells.
(a)U937cellsweretreatedwithoutorwiththeindicatedconcentrationsofPEITCfor
3 and 6h. (b) U937 cells were treated without or with 8mM PEITC for 0.5, 1, 2, 3, 4,
6, 12, and 24h. Total cellular extract were prepared and subjected to western blot
analysis using antibody against XIAP, Mcl-1, Bcl-2, Bcl-xL, Bax, and Bad. (c) U937
cells were treated without or with the indicated concentrations of PEITC for 3 and
6h.(d) U937 cells were treated without or with 8mM PEITC for 0.5, 1, 2, 3, 4, 6, 12,
and24h.Totalcellularextractwerepreparedandsubjectedtowesternblotanalysis
using antibodies against cell signaling molecules, including phospho-Akt, Akt,
phospho-JNK, and JNK. Each lane was loaded with 30mg protein. Blots were
subsequently stripped and reprobed with antibody against b-actin to ensure
equivalent loading and transfer. Two additional studies yielded equivalent results
PEITC exhibits antileukemic activity
N Gao et al
2
Cell Death and DiseaseDose-dependent study indicated that exposure of U937 cells
to PEITC at 2mM resulted in a slight reduction in levels of
phospho-Akt (Ser473). These events became apparent at
concentration of 4 and 6mM. The complete blockage of levels
of phospho-Akt (Ser473) was noted after drug exposure at
8mM (Figure 2c). However, PEITC had little or no signiﬁcant
effects on total Akt. In addition, treatment of cells with PEITC
resulted in a dramatic increase in levels of phospho-JNK, but
had no effect on levels of total JNK. A time-course study
showed that exposure of U937 cells to 8mM PEITC resulted
in modest decrease in levels of phospho-Akt and a increase
in the activation of JNK as early as 2h after drug exposure.
These events became apparent at 4 and 6h and reached
near-maximal effects at 12 or 24h (Figure 2d). In contrast,
PEITC had little or no effect on expression of total or
phospho-mTOR, phospho-ERK, and phospho-p38 (data not
shown). These results suggest that a pronounced
inactivation of Akt and an activation of JNK may have
important roles in PEITC-induced apoptosis in U937 human
leukemia cells.
PEITC has similar effects on apoptosis in multiple
human leukemia cell types and primary AML
blasts. Various human leukemia cell types, including U937
myelomonocytic, HL-60 promyelocytic, and Jurkat
T-lymphoblastic leukemic cells, were exposed to 8mM PEITC
for 6h, after which apoptosis was determined by Annexin
V/PI analysis. As shown in Figure 3a, treatment with PEITC
resulted in dramatic increase in apoptosis in these cell lines.
Consistent with these results, exposure of cells to PEITC
revealed signiﬁcant increases in cleavage/activation of
caspase-3, -8, and -9, as well as PARP degradation
(Figure 3b). Similarly, exposure of various human leukemia
cells to PEITC resulted in marked decrease in expression of
Mcl-1 (Figure 3c). Comparable inactivation of Akt and
activation of JNK were also observed in these cell lines
after drug exposure (Figure 3d).
Furthermore, exposureofblastsfrom17patientswithacute
myeloid leukemia (AML) to 8mM PEITC for 24h revealed
marked increase in cell death (Figure 3e), accompanied by
cleavage/activation of caspase-3, -8, and -9, as well as PARP
degradation (Figure 3f). In contrast, the PEITC regimen
exerted only minimal toxicity toward normal human peripheral
blood mononuclear cells (Figure 3g). Taken together, these
ﬁndings indicate that PEITC selectively triggers apoptosis in
multiple human leukemia cells lines as well as in primary AML
blasts, but displays signiﬁcantly less toxicity toward normal
hematopoietic cells.
PEITC lethality is associated with the caspase-
independent inactivation of Akt and activation of
JNK. To assess whether PEITC-induced inactivation of Akt
and activation of JNK are dependent on caspases activation,
the pan-caspase inhibitor Z-VAD-FMK was used. Co-
treatment of cells with the caspase inhibitor Z-VAD-FMK,
which abrogated PEITC-induced apoptosis (Figure 4a),
caspase activation, and PARP degradation (Figure 4b),
failed to prevent Akt inactivation, JNK activation, as well as
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Figure 3 Phenethyl isothiocyanate (PEITC) had similar effects on apoptosis in other human leukemia cell lines as well as primary acute myeloid leukemia (AML) human
leukemia cells. U937, Jurkat, and HL-60 cells were treated without or with 8mM PEITC for 6h, (a) after which the percentage of apoptotic cells was determined by Annexin
V/propidium iodide (PI) staining and ﬂow cytometry as described in Materials and Methods. The values obtained from Annexin V/PI assays represent the mean±standard
deviation (S.D.) for three separate experiments. **Values for cells treated with PEITC were signiﬁcantly increased compared with values obtained for control by Student’s
t-test;Po0.01.Totalcellularextractswerepreparedandsubjectedtowesternblotanalysisusingantibodiesagainstpoly(ADP-ribose)polymerase(PARP),cleaved-caspase-
3 (C-Caspase-3), caspase-8, C-Caspase-9 (b), anti-apoptotic protein Mcl-1 (c), and cell signaling molecules including phospho-Akt, Akt, phospho-Jun N-terminal kinase
(JNK), and JNK (d). (e) Blasts from 17 patients with AML were isolated as described in Materials and Methods. After washing and counting, isolated mononuclear cells were
treatedwithoutorwith8mMPEITCfor24h,afterwhichthepercentageofapoptoticcellswasdeterminedbyAnnexinV/PIstainingandﬂowcytometry.(f)Totalcellularextracts
ofblastsfromtwoAMLpatients(P1andP6)werepreparedandsubjectedtowesternblot analysisusingantibodiesagainstPARP,C-Caspase-3,caspase-8,andC-Caspase-
9. (g) Normal peripheral blood mononuclear cells were treated without or with 8mM PEITC for 24h, after which the percentage of apoptotic cells was determined by Annexin
V/PI staining and ﬂow cytometry as described in Materials and Methods. The values represent the means±S.D. for three replicate determinations. For western blot analysis,
each lane was loaded with 30mg of protein; blots were subsequently stripped and reprobed with antibodyagainst b-actin to ensure equivalentloading. Two additionalstudies
yielded equivalent results
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Cell Death and DiseaseMcl-1 downregulation induced by PEITC (Figures 4c and d).
Such ﬁndings indicate that inactivation of Akt, activation
of JNK, and downregulation of Mcl-1 mediated by PEITC do
not simply represent a secondary, caspase-dependent
event.
The effects of interruption of PI3K/Akt signaling pathway
on PEITC-induced apoptosis. To assess the effects of
interruption of the PI3K/Akt pathway on the lethal actions of
PEITC, U937 cells were exposed to sublethal concentration
of PEITC (i.e., 4mM; B25%) in the presence of PI3K inhibitor
LY294002 (i.e., 20mM), after which apoptosis was assessed.
As shown in Figure 5a, co-administration of LY294002 with
PEITC resulted in a pronounced increase apoptosis in U937
cells (Po0.01 versus PEITC treatment alone). Similarly,
co-administration of PEITC and LY294002 at concentrations
that were ineffective or marginally effective by themselves
resulted in pronounced increase in the activation of caspase-
3, -8, and -9, and PARP degradation (Figure 5b). Combined
treatment with PEITC and LY294002 also resulted in
the potentiation of Mcl-1 downregulation (Figure 5c).
Furthermore, co-administration of PEITC and LY294002
essentially abrogated expression of the phosphorylated Akt
(Ser473) and potentiated activation of JNK (Figure 5d).
Because PEITC inhibits phosphorylation of Akt and functions
like Akt inhibitor, we used 4mM PEITC instead of 8mM.
To characterize the functional role of perturbations in Akt in
the apoptotic response of leukemia cells to PEITC, U937 cells
ectopically expressing constitutive active form of Akt (Akt-CA)
and the dominant-negative Akt (Akt-DN) were employed. As
showninFigure6a,exposureofpcDNA3.1vectorcontrolcells
and Akt-DN cells to PEITC at a concentration of 8mM for 6h
resulted in signiﬁcant increase in apoptosis. However,
apoptosis was strikingly attenuated in Akt constitutively active
cells after drug exposure. Consistent with these results, the
activation of caspases and cleavage of PARP were also
markedly attenuated in Akt-CA cells (Figure 6b). In addition,
enforced activation of Akt efﬁcaciously blocked PEITC-
mediated Mcl-1 downregulation (Figure 6c). Western blot
analysis displayed marked increase in levels of total and
phospho-Akt in Akt-CA cells. PEITC failed to inhibit phos-
phorylation of Akt in these Akt cells (Figure 6d). Interestingly,
the ability of PEITC to induce JNK activation was essentially
abrogated in Akt-CA cells (Figure 6d). Taken together, these
ﬁndings indicate that inactivation of the Akt pathway has a
critical role in PEITC-related lethality and that this event lies
upstream of Mcl-1 downregulation and JNK activation.
Effects of pharmacological and genetic inhibition of JNK
on PEITC-related lethality. The functional role of JNK
activation in PEITC lethality was then investigated using both
pharmacological and genetic approaches. As shown in
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Figure 4 Phenethyl isothiocyanate (PEITC)-induced Mcl-1 downregulation, Akt
inactivation, and Jun N-terminal kinase (JNK) activation were not dependent
on caspase activation. U937 cells were pretreated with the caspase
inhibitor benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-ﬂuoromethylketone (Z-VAD-
FMK) (10mM) for 1h, followed by treatment with 8mM of PEITC for 3 and 6h.
(a) Cells were stained with Annexin V/propidium iodide (PI). Apoptosis was
determinedusingﬂowcytometryasdescribedinMaterialsandMethods.Thevalues
obtained from Annexin V assays represent the means±standard deviation (S.D.)
for three separate experiment. **Values for cells treated with PEITC and Z-VAD-
FMK were signiﬁcantly reduced compared with values obtained for PEITC alone by
Student’s t-test; Po0.01. Total protein extracts were prepared and subjected to
western blot assay using antibodies against apoptosis-related proteins, including
PARP, cleaved-caspase-3 (C-Caspase-3), caspase-8, and C-Caspase-9
(b); antiapoptotic protein Mcl-1 (c); as well as cell signaling proteins, including
phospho-Akt, Akt, phospho-JNK, and JNK (d). For western blot analysis, each lane
was loaded with 30mg of protein, and blots were subsequently stripped and
reprobed with antibody against b-actin to ensure equivalent loading
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Figure 5 Inhibition of phosphoinositide 3-kinase (PI3K)/Akt by LY294002 (LY)
enhanced phenethyl isothiocyanate (PEITC)-induced apoptosis in human leukemia
cells.U937cellswerepretreatedwith20mMofLYfor1h,followedbytheadditionof
4mMofPEITCfor3and6h.(a)CellswerestainedwithAnnexinV/propidiumiodide
(PI), and apoptosis was determined using ﬂow cytometry as described in Materials
and Methods. The values obtained from Annexin V/PI assays represent the
means±standard deviation (S.D.) for three separate experiments. **Values for
cellstreatedwithPEITCandLYincombinationweresigniﬁcantlygreaterthanthose
for cells treated with PEITC alone by Student’s t-test; Po0.01. Total cellular
extracts were prepared as described in Materials and Methods, and subjected to
western blot analysis using antibodies against apoptosis-related proteins, including
poly(ADP-ribose) polymerase (PARP), cleaved-caspase-3 (C-Caspase-3),
caspase-8, and C-Caspase-9 (b), antiapoptotic protein Mcl-1 (c), and cell signaling
molecules, including phospho-Akt, Akt, phospho-Jun N-terminal kinase (JNK), and
JNK (d). For western blot assay, each lane was loaded with 30mg of protein; blots
were subsequently stripped and reprobed with antibody against b-actin to ensure
equivalent loading. Two additional studies yielded equivalent results
PEITC exhibits antileukemic activity
N Gao et al
4
Cell Death and DiseaseFigure 7a, co-administration of a non-toxic concentration of
SP600125 (i.e., 10mM) with a toxic concentration of PEITC
(8mM; B75% for 6h) resulted in a pronounced decrease in
apoptosis (i.e., to B30%). Consistently, co-administration of
SP600125 also markedly attenuated PEITC-mediated
caspases activation and PARP degradation (Figure 7b).
Co-administration of SP600125 also attenuated PEITC-
induced Mcl-1 downregulation and JNK activation (Figures
7c and d). As SP600125 is not completely speciﬁc for JNK,
14
a genetic approach utilizing JNK1 siRNA was employed. As
shown in Figure 7f, transient transfection of U937 cells with
JNK1 siRNA reduced the expression of JNK1 to 50%
compared with control cells, and resulted in a signiﬁcant
reduction in PEITC-mediated apoptosis (Po0.01 versus
control siRNA cells). Taken together, these ﬁndings
indicate that JNK activation has an important functional role
in PEITC-related lethality.
PEITC inhibits tumor growth of U937 xenograft model
accompanied by striking induction of apoptosis,
inactivation of Akt, and activation of JNK. To assess
whether our in vitro observations could be translated into an
animal model system, NOD/SCID mice were inoculated
intraperitoneally (i.p.) with U937 cells, after which mice
received injections with vehicle or PEITC (50mg/kg, i.p.) for
20 days starting 3 days after the injection of U937 human
leukemia cells. As shown in Figure 8a, treatment with PEITC
resulted in a modest, but signiﬁcant suppression of tumor
growth 10 days following drug exposure (Po0.05 versus
vehicle control). These events became more apparent
15 and 20 days after drug exposure (Po0.01 between
PEITC treatment and vehicle control). In contrast, no
statistically signiﬁcant change in body weight was noted
comparing vehicle control and PEITC regimen (Figure 8b).
Moreover, the mice of PEITC group did not exhibit any other
signs of toxicity such as agitation, impaired movement and
posture, indigestion or diarrhea, and areas of redness or
swelling. These results indicated that PEITC administration
signiﬁcantly inhibited tumor growth of U937 xenograft without
causing any side effects and/or toxicity to the mice.
The morphological changes and induction of apoptosis in
U937 cells in vivo were investigated using hematoxylin and
eosin (H&E) staining and TUNEL assay. As shown in
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Figure 6 Enforced activation of Akt markedly protects cells from phenethyl
isothiocyanate (PEITC)-induced apoptosis. U937 cells were stably transfected with
constitutively active forms of Akt (Akt-CA), dominant-negative Akt mutant (Akt-DN),
and an empty vector (pcDNA3.1) as described in Materials and Methods. All cells
were then treated with 8mM of PEITC for 6h. (a) After treatment, apoptosis was
determined using Annexin V- ﬂuorescein isothiocyanate (FITC) assay as described
in Materials and Methods. **Values for Akt-CA cells treated with PEITC were
signiﬁcantly decreased compared with those for pcDNA3.1 and Akt-DN cells by
Student’s t-test; Po0.01. Total cellular extracts were prepared and subjected to
western blot analysis using antibodies against apoptosis-related proteins, including
poly(ADP-ribose) polymerase (PARP), cleaved-caspase-3 (C-Caspase-3),
caspase-8, and C-Caspase-9 (b), antiapoptotic protein Mcl-1 (c), and cell signaling
proteins, including phospho-Akt, Akt, phospho-Jun N-terminal kinase (JNK), and
JNK (d). For western blot assay, each lane was loaded with 30mg of protein; blots
were subsequently stripped and reprobed with antibody against b-actin to ensure
equivalent loading. Two additional studies yielded equivalent results
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Figure 7 Effects of pharmacological and genetic interruption of Jun N-terminal
kinase (JNK) on phenethyl isothiocyanate (PEITC)-induced apoptosis. U937 cells
werepretreatedwith10mMofJNKinhibitor,SP600125(SP),for1h,followedbythe
addition of 8mM of PEITC for 3 and 6h. (a) Cells were stained with Annexin V/PI,
and apoptosis was determined using ﬂow cytometry as described in Materials and
Methods. The values obtained from Annexin V/PI assays represent the
means±standard deviation (S.D.) for three separate experiments. **Values for
cells treatedwith PEITC and SP were signiﬁcantly less than those obtained for cells
treated with PEITC alone by Student’s t-test; Po0.01. After treatment,total cellular
extracts were prepared and subjected to western blot analysis using antibodies
against poly(ADP-ribose) polymerase (PARP), cleaved-caspase-3 (C-Caspase-3),
caspase-8, and C-Caspase-9 (b), Mcl-1 (c), as well as cell signaling proteins,
including phospho-JNK, and JNK (d). (e) U937 cells were transiently transfected
with JNK1small interferingRNA (siRNA)oligonucleotides or controlsandincubated
for 24h at 371C, after which cells were treated with 8mM of PEITC for 6h. Total
cellular extracts were prepared and subjected to western blot analysis using
antibody against JNK1 and JNK2. Apoptosis was determined using the Annexin
V-FITCassayasdescribedin MaterialsandMethods.**Valuesforcellstreatedwith
PEITC after transfection with JNK1 siRNA oligonucleotides were signiﬁcantly
decreased compared with those for control cells treated with PEITC by Student’s
t-test; Po0.01
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Cell Death and DiseaseFigure 8c, the sections of U937 xenografts from mice treated
with PEITC exhibited a reduced number of cancer cells, with
signs of necrosis with inﬁltration of inﬂammatory cells (i.e.,
phagocytic cells), ﬁbrosis, as well as apoptotic regions,
identiﬁed by their amorphous shape and condensed nuclei.
Moreover, exposure to PEITC resulted in a striking induction
of apoptosis in tumor cells, with signs of numerous dark
brown-colored apoptotic cells. Also, exposure to PEITC
caused a rapid increase in immunoreactivity for the cleaved
form of PARP and caspase-3, indicative of apoptosis.
The preceding ﬁndings implied that downregulation of
Mcl-1, inactivation of Akt, and activation of JNK might have
important roles in PEITC-mediated lethality in U937 cells
in vitro. To evaluate whether the preceding in vitro ﬁndings
would be operative in vivo, immunohistochemistry analysis
was performed to evaluate the expression of Mcl-1, phospho-
Akt, and phospho-JNK in tissue sections of U937 xenografts.
As shown in Figure 8d, immunostaining of tumors from mice
treated with PEITC showed that the levels of Mcl-1 and
phospho-Akt were decreased and phospho-JNK was
increased. Collectively, these ﬁndings suggest that disruption
of Akt/JNK/Mcl-1 signaling may also contribute to lethality
induced by PEITC in vivo.
Discussion
TheseresultsindicatethatPEITCmarkedlyinducescelldeath
in multiple human leukemia cell types and primary human
AML blast cells. Our results also provide detailed molecular
mechanistic information as to how PEITC exerts its apoptotic
effects on human leukemia cells (i.e., by inactivation of Akt,
activation of JNK, and downregulation of Mcl-1). Previous
studies indicated that PEITC was shown to induce apoptosis
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Figure 8 Phenethyl isothiocyanate (PEITC) inhibits tumor growth and induces apoptosis in U937 xenograft animal model. Twenty non-obese diabetic/severe combined
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treatment with PEITC (50mg/kg, intraperitoneally (i.p.), daily) or with vehicle control solvent as described in Materials and Methods. (a) Average tumor volume in vehicle
control mice and mice treated with 50mg/kg PEITC. Data are means±standard deviation (S.D.) (10 mice per group with tumors implanted on right ﬂank of each mouse).
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20 days, tumor tissues were also sectioned and subjected to immunohistochemistry using antibodies against Mcl-1, phospho-Akt, and phospho-Jun N-terminal kinase (JNK).
The sections were lightly counterstained with hematoxylin and photographed with a Scan Scope. Original magniﬁcation  400
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Cell Death and Diseasein many cancer cells such as prostate,
8,11 breast,
15 lung,
16
hepatoma,
17 colon,
18 as well as leukemia.
13 Mechanism of
PEITC-induced apoptosis is not fully understood, but known
cellular responses to this promising agent include ERK,
8
JNK,
9 nuclear factor-kB (NF-kB),
19 and ROS-mediated
apoptosis induction.
11,12 Presently, little information is avail-
able concerning the functional role of the Akt pathway in
mediating PEITC-induced lethality, particularly in malignant
hematopoietic cells. The results of this study show that Akt
inactivation not only represents the primary cause, but also
have an important functional contribution in JNK activation,
Mcl-1 downregulation, and lethality induced by PEITC.
Akt is a serine–threonine kinase intimately involved in the
regulation of cell survival.
20 It is activated by recruitment to the
cell membrane through the actions of PI3K, which in turn is
regulated by the PTEN phosphatase,
21 mutations of which are
among the most commonly encountered in human cancers.
22
Akt is involved in activation/phosphorylation of numerous down-
stream targets implicated in the modulation of diverse pathways
governing cell survival decisions, including those associated with
glycogen synthase kinase (GSK),
23 m-TOR/p70rsk,
24 and NF-
kB,
25 among others. Most notably, PEITC exposure resulted in
diminished,ratherthanincreased,Aktphosphorylation.Although
it would be tempting to attribute this phenomenon to PTEN
activation,thefactthatU937cellsdonotexpresswild-typePTEN
argueagainstthisnotion.
26AmorelikelypossibilityisthatPEITC,
through a mechanism yet to be elucidated, blocks the actions of
PI3K. The ﬁnding that LY29004, an inhibitor of PI3K, enhanced
the lethality of PEITC by blocking the activation of Akt and one or
more of its downstream targets (i.e., Mcl-1) is potentially
consistent with this concept.
In fact, the caspase-dependent downregulation of Akt is a
well-described phenomenon.
27 Our present results indicate
that PEITC induces apoptosis by activating both caspase-8
and -9, along with caspase-3, raising the possibility that Akt
inactivationmight representa consequenceofengagementof
thecaspasecascade.Inthisstudy,co-treatmentofU937cells
with the pan-caspase inhibitor Z-VAD-FMK, which abrogated
PEITC-induced activation of caspases (i.e., caspase-3, -8,
and -9) and apoptosis, failed to prevent Akt inactivation,
arguing strongly that factors other than caspase-mediated
events are involved in this phenomenon.
The bulk of evidence suggests that in human leukemia
cells, PEITC-induced Akt inactivation has a critical functional
role in mediating PEITC lethality. Signiﬁcantly, enforced
activation of Akt and prevention of PEITC-induced Akt
downregulation largely reversed the lethal consequences of
PEITC exposure, including caspase activation, PARP clea-
vage, and apoptosis. It is worth noting that PEITC exposure
resulted in the downregulation of Mcl-1, an antiapoptotic
protein that may play a particularly important role in regulating
apoptosis in malignant hematopoietic cells.
28 It has been
reported that the antiapoptotic gene Mcl-1 is upregulated by
the PI3K/Akt signaling pathway,
29 and downregulation of Mcl-1
by inhibition of PI3K/Akt pathway is required for cell death.
30
The ﬁnding that enforced activation of Akt largely blocked
PEITC-mediated downregulation of Mcl-1 may signiﬁcantly
contribute to PEITC-mediated lethality.
Induction of caspase activation and apoptosis by PEITC
was also associated with the activation of the stress-related
JNKpathway.JNKbelongstothesuperfamily ofMAPkinases
that are involved in the regulation of cell proliferation,
differentiation, and apoptosis.
31 The critical role of JNK has
been shown in the lethal effects of diverse cytotoxic stimuli,
including ceramide,
32 Fas ligand,
33 UV,
34 among others. The
ﬁnding that pharmacological and genetic interruption of the
JNK pathway attenuated PEITC-mediated lethality indicates
thatstresspathwayshaveacriticalfunctionalroleinapoptosis
induction by this agent. Interestingly, co-administration with
PI3K inhibitor LY294002, which potentiate inactivation of Akt,
enhanced JNK activation and apoptosis induced by PEITC.
Furthermore, enforced activation of Akt not only blocked
PEITC-mediated caspase activation and apoptosis, but also
prevented the striking increase in JNK activation, raising the
possibility that one of the mechanisms by which Akt protects
cells from PEITC lethality is by opposing JNK activation. This
phenomenon might be explained by the following lines of
evidence. Firstly, ASK-1, the protein that activates JNK, is a
target of Akt inhibitory phosphorylation. Phosphorylation by
Akt inhibited JNK activity, which is mediated by ASK1,
providing the direct link between Akt and JNK.
20 Secondly,
the interaction between Akt and JIP1 inhibited JIP1-mediated
potentiation of JNK activity by decreasing JIP1 binding to
speciﬁc JNK pathway kinases, suggesting that Akt interaction
with JIP1 acts as a negative switch for JNK activation.
35
Previous studies have shown that PEITC markedly inhibits
tumor growth of human prostate and ovarian xenografts through
the induction of apoptosis.
11,12,36,37 Little is known, however,
about inhibitory effects of PEITC on tumor growth of human
leukemia xenograft model. The results from in vivo studies have
shown that PEITC exhibits signiﬁcant inhibitory effects on the
growth of U937 leukemia tumor xenograft. To understand
whether the apoptotic mechanism in vitro is identical to those
in vivo, we next examined apoptosis in tumor specimens
obtained from control and PEITC-treated animals using TUNEL
staining. The increase of TUNEL-positive cells was detected in
thePEITC-treatedgroupcomparedwiththecontrolgroup,which
provides the apoptotic evidence in PEITC-treated U937
xenograft mice. This is the ﬁrst report that describes an effective
extrapolation of the in vitro apoptosis-inducing effects of PEITC
on the leukemia cells to the in vivo situation. We also found that
administration of PEITC resulted in marked increase in
activation/cleavage of caspase-3 and PARP in tissue sections
of U937 tumor xenograft, further conﬁrming the apoptotic
mechanism observed in vivo. To dissect the possible mechan-
isms in which the apoptotic signaling was triggered, we also
examined the expression levels of phospho-Akt, phospho-JNK,
and Mcl-1 in tissue sections of U937 xenograft tumor using
immunohistochemistry analysis. Our results suggest that
suppression of the p-Akt and Mcl-1 and upregulation of p-JNK
were closely correlated with the reduction of U937 tumor
xenografts. These results are consistent with the in vitro data.
In addition, the lack of toxicity in a mouse model points to PEITC
as a potential candidate for chemopreventive and chemother-
apeutic use. These data suggest that PEITC can be a possible
anticancer agent in the treatment of leukemia and possibly other
hematological malignancies.
In summary, these ﬁndings indicate that PEITC effectively
induces cell death in human leukemia cells, including primary
leukemia blasts, as well as in leukemia xenografts. This effect
PEITC exhibits antileukemic activity
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Cell Death and Diseaseoccurs in association with the inactivation of Akt, activation of
JNK, as well as downregulation of Mcl-1, such ﬁndings could
have chemopreventive or chemotherapeutic implications.
Materials and Methods
Cell lines. U937, HL-60, and Jurkat cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA) and maintained in RPMI 1640
medium containing 10% fetal bovine serum (FBS). The Akt-CA, which is an
Myc-tagged myr-Akt, and the Akt-DN were kindly provided by Dr. Richard Roth
(Stanford University, School of Medicine, Stanford, CA, USA), and were subcloned
into the pcDNA3.1. U937 cells were stably transfected with Akt-CA and Akt-DN
using the Amaxa nucleofector (Koeln, Germany) as recommended by the
manufacturer. Stable single-cell clones were selected in the presence of 400mg/
ml of geneticin.Thereafter, theexpressionof Akt fromeach cell clonewas analyzed
by western blot analysis.
Peripheral blood samples for the in vitro studies were obtained from 17 patients
with newly diagnosed or recurrent AML after informed consent. Approval was
obtainedfrom the SouthwestHospital (Chongqing, China) institutional reviewboard
for these studies. AML blasts were isolated by density gradient centrifugation over
Histopaque-1077 (Sigma Diagnostics, St. Louis, MO, USA) at 400 g for 38min.
Isolated mononuclear cells were washed and assayed for total number and viability
usingTrypanblueexclusion.Blastsweresuspendedat 8 10
5/mlandincubatedin
RPMI 1640 medium containing 10% FBS in 24-well plates. Fresh normal peripheral
blood mononuclear cells were purchased from Allcells (Emeryvill, CA, USA). After
washing and enumerating, cells were suspended at 8 10
5/ml before treatment.
Reagents and antibodies. PEITC was purchased from LKT Laboratories
(St.Paul,NM, USA).LY294002,SP600125,andZ-VAD-FMKwerepurchasedfrom
EMD Biosciences (La Jolla, CA, USA). Antibodies against Akt, JNK, phospho-JNK,
and b-actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); cleaved
caspase-3, cleaved caspase-9, phospho-Akt (Ser473), and Bcl-xL were from Cell
Signaling Technology (Beverly, MA, USA); XIAP, Mcl-1, Bax, and Bad were from
BDPharMingen;PARPwasfromBiomol (PlymouthMeeting,PA,USA);caspase-8was
from Alexis (Carlsbad, CA, USA) and Bcl-2 was from Dako (Carpinteria, CA, USA).
RNA interference and transfection. U937 cells (1.5 10
6) were
transfected with 1mg JNK1-annealed dsRNAi oligonucleotide 50-CGUGGGAU
UUAUGGUCUGUGTT-30/30-TTGCACCUAAAUACCAGACAC-50 (Orbigen, San
Diego, CA, USA) using the Amaxa nucleofectort (Koeln, Germany) as
recommended by the manufacturer. After incubation at 371C for 24h, transfected
cellsweretreatedwithPEITC,andsubjectedtodeterminationofapoptosisandJNK
expression using Annexin V/PI and ﬂow cytometry and western blot analysis as
described below.
Apoptosis. The extent of apoptosis in leukemia cells was evaluated by ﬂow
cytometric analysis using FITC-conjugated Annexin V/propidium iodide (BD
PharMingen) staining as per the manufacturer’s instructions as described
previously.
38 Both early apoptotic (Annexin V-positive, PI-negative) and late
apoptotic (Annexin V-positive and PI-positive) cells were included in cell death
determinations.
Western blot analysis. The total cellular samples were washed twice with
ice-cold PBS and lysed in 1 NuPAGE LDS sample buffer supplemented with
50mM dithiothreitol. The protein concentration was determined using Coomassie
Protein Assay Reagent (Pierce, Rockford, IL, USA). In total, 30mg of sample
proteinswereseparatedbySDS-PAGEandtransferredtonitrocellulosemembrane.
Membraneswereblockedwith 5%fat-freedrymilkin1 Tris-bufferedsaline(TBS)
and incubated with antibodies. Protein bands were detected by incubating with
horseradish peroxidase-conjugated antibodies (Kirkegaard and Perry Laboratories,
Gaithersburg, MD,USA)andvisualizedwith enhancedchemiluminescencereagent
(Perkin-Elmer, Boston, MA, USA).
Xenograft. NOD/SCID mice (5 weeks old) were purchased from Vital River
Laboratories (Beijing, China). All animal studies were conducted according to
protocols approved by the Institutional Animal Care and Use Committee of the
University. U937 cells (2 10
6/0.2ml per mouse) were suspended in sterile PBS
and injected subcutaneously into the right ﬂank of the mice. Mice were randomized
into two groups of 10 mice per group. At 3 days after tumor inoculation, the
treatment group received PEITC (50mg/kg, i.p. for 20 days). The control group
received an equal volume of solvent control. Tumor size and body weight were
measured after treatment at various time intervals throughout the study. At the
terminationoftheexperiment,micewerekilledat24hafterthelastadministrationof
compound. The tumors were excised and weighed. Tumors were collected at
selected times and ﬁxed in paraformaldehyde. Parafﬁn-embedded tissues were
sectioned and processed for H&E, TUNEL, and immunohistochemical staining.
TUNEL. The apoptotic cells in tissue samples were detected using an In Situ
Cell Death Detection kit (Roche, Mannheim, Germany) according to the
manufacturer’s manual. After deparafﬁnization and permeabilization, the tissue
sections were incubated in proteinase K for 15min at room temperature. The
sections were then incubated with the TUNEL reaction mixture that contains
terminal deoxynucleotidyl transferase and ﬂuorescein-dUTP at 371C for 1h. After
washing three times with PBS, the sections were incubated with the Converter-
POD, which contains anti-ﬂuorescein antibody conjugated with horse-radish
peroxidase (POD) at room temperature for 30min. After washing three times with
PBS, the sections were incubated with 0.05% 3-30-diaminobenzidine
tetrahydrochloride and analyzed under light microscope.
Histological and immunohistochemical evaluation. At the
termination of experiments, tumor tissues from representative mice were
sectioned, embedded in parafﬁn, and stained with H&E for histopathological
evaluation. For immunohistochemical analysis, tissue sections 4mm in thickness
were dewaxed and rehydrated in xylene and graded alcohols. Antigen retrieval was
performedwith0.01McitratebufferatpH6.0for20minina951Cwaterbath.Slides
were allowed to cool for another 20min, followed by sequential rinsing in PBS and
TBS-T buffer. Endogenous peroxidase activity was quenched by incubation in
TBS-T containing 3% hydrogen peroxide. Each incubation step was carried out at
room temperature and was followed by three sequential washes (5min each) in
TBS-T. After blocking with 10% goat serum for 1h, sections were incubated with
primary antibodies, washed three times in PBS, incubated with biotinylated
secondary antibody for 1h, followed by incubation with a streptavidin–peroxidase
complex for another 1h. After three additional washes in PBS, diaminobenzidine
workingsolutionwasapplied.Finally,theslideswerecounterstainedinhematoxylin.
Statistical analysis. Tumor volumes, body weights, and percentage of
apoptotic cells were represented as mean±S.D. The statistical signiﬁcance of the
difference between control and PEITC-treated groups was evaluated using
Student’s t-test. Po0.05 or 0.01 were considered signiﬁcant.
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